{
    "type": "ETP",
    "ucits": false,
    "leverage": true,
    "derivatives": true,
    "swaps": true,
    "inverse": true,
    "replication_method": "synthetic",
    "complex_factors": [
        "Leverage",
        "Synthetic replication via swaps",
        "Counterparty risk",
        "Collateralized swap exposure",
        "Daily leverage reset and compounding effect",
        "Opaque payoff structure",
        "High risk rating (7/7)",
        "Underlying exposure to a single equity (BP p.l.c.) with 3x short leverage"
    ],
    "classification": "complex",
    "supporting_data": "The product is a 3x short leveraged Exchange Traded Product (ETP) that seeks to replicate -3 times the daily performance of BP p.l.c. via a swap with Natixis as the swap provider. This swap-based synthetic replication introduces counterparty risk and collateral risk, which are complex features under MiFID II. The product uses significant leverage (3x short), which is beyond UCITS limits and inherently complex. The daily reset of leverage causes a compounding effect, making the return over periods longer than one day difficult to understand for retail investors. The product is classified with the highest risk rating (7/7), reflecting very high risk and complexity. The structure is opaque due to the swap and collateral arrangements, and the payoff profile is non-linear and difficult for retail investors with basic knowledge to grasp. According to MiFID II Article 254, Delegated Regulation EU 2017/565 Article 57, and ESMA guidelines, such features (synthetic replication, embedded swaps, leverage, counterparty risk) classify the product as complex. The product is not UCITS compliant but an ETP. Therefore, it requires an appropriateness assessment and cannot be sold on an execution-only basis without such assessment."
}